Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2021-05-11 Interim / Quarterly Rep…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 March 2021. It contains detailed financial statements (Consolidated statement of income, financial position, cash flow), segment reporting, and management analysis of business performance. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-11 German
Biotest AG: Biotest AG opens 10th plasma collection centre in Hungary
Regulatory Filings Classification · 100% confidence The document is a press release dated May 6, 2021, announcing that Biotest AG opened its 10th plasma collection center in Hungary. It contains general corporate news, operational updates, and boilerplate information about the company, investor relations contacts, and stock listings. It is not a formal financial report (like 10-K or IR), a transcript (CT), a dividend notice (DIV), or a management discussion (MDA). Since it is a general corporate announcement disseminated via DGAP (a service often used for regulatory news dissemination), and it doesn't fit into the more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Earnings Release (ER), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous news releases.
2021-05-06 English
Biotest AG: Biotest confirms good tolerability and efficacy of Intratect(R) in primary and secondary immunodeficiencies in an observational study
Regulatory Filings Classification · 99% confidence The document is a press release dated April 22, 2021, announcing the results of an observational study regarding the drug Intratect(R). It details clinical findings, patient satisfaction, and tolerability. This type of announcement, which communicates specific operational or clinical news rather than mandatory periodic financial reports (like 10-K or IR) or formal shareholder meeting materials, typically falls under general corporate news or regulatory announcements. Since it is not a formal Earnings Release (ER) which focuses on financial metrics, nor an Investor Presentation (IP), and it is a specific announcement disseminated via DGAP (a service often used for regulatory news), the most appropriate classification is Regulatory Filings (RNS) as a general corporate news item that doesn't fit a more specific category like ER, CT, or DIV. It is not a short announcement pointing to a separate report, so RPA is not the best fit; it *is* the announcement itself.
2021-04-22 English
Biotest Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 11.05.2021 in Dreieich mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is titled 'Bekanntmachung der Einberufung zur Hauptversammlung am 11.05.2021' (Announcement of the Convocation to the General Meeting on 11.05.2021) and explicitly mentions 'ERGÄNZUNG DER TAGESORDNUNG ZUR HAUPTVERSAMMLUNG DER BIOTEST AG AM 11. MAI 2021' (Supplement to the Agenda for the General Meeting of Biotest AG on May 11, 2021). It details shareholder requests to add items to the agenda, specifically concerning the removal and re-election of a Supervisory Board member and a request for a special investigation (Sonderprüfung). This content directly relates to the formal proceedings and agenda items of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2021-04-21 German
Biotest AG: Biotest accelerates fibrinogen phase III study with additional patient group
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 7, 2021, disseminated via DGAP-News, announcing a clinical development update for Biotest AG's fibrinogen concentrate (BT524). It details the acceleration of a Phase III study (AdFIrst) and mentions that the results will form the basis for marketing authorization. This type of announcement, focusing on clinical trial progress, regulatory milestones, and product development news, is typically classified as a general corporate announcement or news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific regulatory filing like DIRS or DIV, the most appropriate category is the general regulatory/news fallback, RNS (Regulatory Filings), as it is a formal corporate news item transmitted through a regulatory news service (DGAP). It is not an announcement *of* a report (RPA), but the report/update itself.
2021-04-07 English
Biotest AG: Biotest exceeds Sales and EBIT forecast in the 2020 financial year
Earnings Release Classification · 100% confidence The document is titled 'Biotest exceeds Sales and EBIT forecast in the 2020 financial year' and contains key financial metrics (Sales, EBIT, EBT, EAT) for the full year 2020 compared to 2019, along with an outlook for 2021. This strongly indicates an announcement of periodic financial results. The header 'DGAP-News: Biotest AG / Key word(s): Annual Results' further confirms this. Since it is an initial announcement summarizing the results rather than the comprehensive 10-K filing itself, it fits the definition of an Earnings Release (ER). Although it covers the full year, the format is that of a press release announcing the results, not the full statutory report. FY 2020
2021-03-31 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.